Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3799 USD | +1.31% | +0.88% | -42.80% |
Business Summary
Number of employees: 18
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -64.72% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -64.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 31/12/01 |
David McClung
DFI | Director of Finance/CFO | 61 | 31/08/13 |
Chief Tech/Sci/R&D Officer | - | 31/07/17 | |
Sujith Shetty
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/19 |
Ian McNiece
CTO | Chief Tech/Sci/R&D Officer | 70 | 07/11/17 |
Anne Laluc
IRO | Public Communications Contact | - | - |
Mark Schwartz
PRN | Corporate Officer/Principal | - | 31/10/18 |
Edward Gillis
PRN | Corporate Officer/Principal | 62 | 31/12/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 31/12/01 |
Jay Moyes
BRD | Director/Board Member | 70 | 31/12/10 |
Richard Krasno
BRD | Director/Board Member | 82 | 23/10/16 |
Director/Board Member | 53 | 17/10/23 | |
Peter Altman
CEO | Chief Executive Officer | 57 | 31/12/01 |
Andrew Blank
CHM | Chairman | 68 | 30/09/19 |
Jim Allen
BRD | Director/Board Member | 69 | 30/09/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,867,520 | 18,818,749 ( 70.04 %) | 0 | 70.04 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.80% | 10.21M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- BCDA Stock
- Company BioCardia, Inc.